Buprenorphine

Major

Buprenorphine Selegiline Anipryl Explained An increased risk of serotonin syndrome or opioid-related toxicity Details Buprenorphine Selpercatinib Retevmo Explained Increased risk of QT interval prolongation Details Buprenorphine Sertindole Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Sertraline Explained Increased risk of serotonin syndrome and an increased risk of QT interval prolongation Details Buprenorphine Sevoflurane Petrem Explained An increased risk of QT interval prolongation, reduced sevoflurane (MAC) exposure needed to produce anesthesia and an increased ri... Details Buprenorphine Sibutramine Explained An increased risk of serotonin syndrome Details Buprenorphine Siponimod Mayzent Explained An increased risk of QT interval prolongation Details Buprenorphine Sodium Oxybate Lumryz Explained An increased risk of CNS depression and clinically significant respiratory depression, obtundation, hypotension, profound sedation... Details Buprenorphine Sodium Phosphate OsmoPrep Explained An increased risk of QT interval prolongation Details Buprenorphine Sodium Phosphate, Dibasic Explained An increased risk of QT interval prolongation Details Buprenorphine Sodium Phosphate, Monobasic Explained An increased risk of QT interval prolongation Details Buprenorphine Solifenacin Vesicare Explained An increased risk of paralytic ileus and an increased risk of QT interval prolongation Details Buprenorphine Sorafenib Nexavar Explained An increased risk of QT interval prolongation Details Buprenorphine Sotalol Betapace Explained An increased risk of QT interval prolongation Details Buprenorphine Spironolactone Aldactone Explained Reduced efficacy of diuretics Details Buprenorphine St John's Wort Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of serotonin syndrome Details Buprenorphine Stramonium Explained An increased risk of paralytic ileus Details Buprenorphine Sufentanil Dsuvia Explained Reduced analgesic effect of SUFentanil and an increased risk of serotonin syndrome Details Buprenorphine Sulpiride Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Sultopride Explained An increased risk of QT interval prolongation Details Buprenorphine Sumatriptan Imitrex Explained An increased risk of serotonin syndrome Details Buprenorphine Sunitinib Sutent Explained An increased risk of QT interval prolongation Details Buprenorphine Suvorexant Belsomra Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Tacrolimus Astagraf Explained An increased risk of QT interval prolongation Details Buprenorphine Taletrectinib Ibtrozi Explained Increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Tamoxifen Nolvadex® Explained An increased risk of QT interval prolongation Details Buprenorphine Tapentadol Nucynta Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome, respiratory depress... Details Buprenorphine Tazemetostat Tazverik Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Buprenorphine Tedizolid Phosphate Sivextro Explained An increased risk of serotonin syndrome Details Buprenorphine Telaprevir Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Telavancin Vibativ Explained An increased risk of QT interval prolongation Details Buprenorphine Telithromycin Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Telotristat Ethyl Xermelo Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Temazepam Restoril Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Terodiline Explained An increased risk of paralytic ileus Details Buprenorphine Tetrabenazine Xenazine Explained An increased risk of QT interval prolongation Details Buprenorphine Tetrazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Thiethylperazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Thiopental Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Thiopropazate Explained An increased risk of respiratory depression and CNS depression Details